Given the potential for a dual MET and AXL inhibitor to minimize the resistance seen to date with antiangiogenic agents, we aimed to investigate the anticancer efficacy and underlying mechanisms of NPS-1034, both in vitro and in vivo, to explore the potential value of alternative adjuvant therapy in RCC. This evidence concerns the gene MET and renal cell carcinoma.